H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Ocuphire Pharma to $18 from $20 and keeps a Buy rating on the shares. The firm adjusted commercialization estimates from 2025 to 2026 model for the company’s partnered asset phentolamine and APX3330.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP:
- Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
- Ocuphire Pharma to Present at Two Investor Conferences in August
- OCUP Earnings this Week: How Will it Perform?
- Ocuphire Pharma price target lowered to $11 from $18 at JonesResearch
- Ocuphire Pharma to highlight APX3330 at ARVO SIG panel, ASRS meeting